The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 09, 2021

Filed:

Aug. 27, 2014
Applicant:

The United States of America, As Represented BY the Secretary, Department of Health & Human Services, Rockville, MD (US);

Inventors:

Nigel H. Greig, Phoenix, MD (US);

Josephine M. Egan, Baltimore, MD (US);

Maire Doyle, Baltimore, MD (US);

Harold W. Holloway, Middle River, MD (US);

Tracy Perry, Baltimore, MD (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/575 (2006.01); A61K 38/26 (2006.01); A61K 38/22 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/575 (2013.01); C07K 14/57563 (2013.01); A61K 38/00 (2013.01); A61K 38/2278 (2013.01); A61K 38/26 (2013.01);
Abstract

The invention relates to novel polypeptide analogs of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogs thereof for neuroprotective and neurotrophic effects.


Find Patent Forward Citations

Loading…